Table 2

Baseline characteristics of the study group as means (SDs) or percentages

Grade of liver brightness0 (n=720)1 (n=124)2 (n=144)pp (0–1)p (1–2)p (0–2)
Age (years)50.9 (6.0)51.9 (6.1)51.5 (5.5)NSNSNSNS
Males44.3% (n=319)65.3% (n=81)59.9% (n=82)<0.001
Hypertensives41.4% (n=298)66.1% (n=82)71.5% (n=103)<0.001
BMI (kg/m²)26.4 (3.9)29.8 (5.0)31.9 (4.9)<0.001<0.001<0.001<0.001
Waist circumference (cm)86.8 (11.9)97.7 (12.0)102.3 (11.8)<0.001<0.001<0.01<0.001
Smoking (pack-years)10.6 (13.3)14.3 (14.9)14.0 (14.6)<0.05NSNSNS
Alcohol consumption (g/week)51.1 (83.0)95.1 (117.0)82.6 (105.1)<0.01<0.05NSNS
Total serum cholesterol (mmol/L)5.6 (1.0)5.8 (1.1)5.8 (1.1)NSNSNSNS
LDL (mmol/L)3.5 (0.9)3.7 (1.1)3.5 (0.9)NSNSNSNS
Triglycerides (mmol/L)1.4 (0.8)1.9 (0.8)2.2 (1.4)<0.001<0.001<0.05<0.001
Systolic blood pressure (mmHg)145.2 (21.5)152.7 (20.3)157.1 (22.2)<0.001<0.01NS<0.001
Fasting insulin (mmol/L)10.8 (7.7)18.2 (10.3)23.8 (17.6)<0.001<0.001<0.001<0.001
Fasting glucose (mmol/L)4.4 (0.7)5.0 (1.4)6.1 (2.8)<0.001<0.001<0.001<0.001
QUICKI0.6 (0.1)0.6 (0.1)0.5 (0.1)<0.001<0.001<0.001<0.001
hs-CRP (ng/mL)3039.4 (6758.3)3981.4 (6068.2)6122.0 (6630.8)<0.001<0.001<0.01<0.001
ALT U/L26.2 (15.5)37.8 (17.1)55.4 (37.7)<0.001<0.001<0.001<0.001
GGT U/L35.1 (33.5)69.7 (116.3)76.8 (92.4)<0.001<0.001<0.01<0.001
Antihypertensive treatment43.6% (n=314)66.9% (n=83)72.9% (n=105)<0.001
Lipid-lowering treatment2.2% (n=16)1.6% (n=2)6.2% (n=9)<0.05
Hypoglycaemic drug1.1% (n=8)1.6% (n=2)10.4% (n=15)<0.001
Type 2 diabetes2.4% (n=17)12.1% (n=15)36.8% (n=53)<0.001
  • ALT, alanine aminotransferase; BMI, body mass index; GGT, γ-glutamyltransferase; hs-CRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein; N, number of participants; NS, not significant; QUICKI, quantitative insulin sensitivity check index.